Rigel Pharmaceuticals reported $21.39M in Gross Profit on Sales for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Alexion Pharmaceuticals ALXN:US $ 1511.1M 71.5M
Amgen AMGN:US $ 5097M 208M
Anika Therapeutics ANIK:US $ 23.02M 2.21M
AstraZeneca AZN:LN 6.04B 15M
Astrazeneca AZN:US 6.04B 15M
Biomarin Pharmaceutical BMRN:US $ 305.2M 69.43M
Bristol Myers Squibb BMY:US $ 9333M 81M
Daiichi Sankyo 4568:JP Y 178489M 428M
Eli Lilly And LLY:US $ 5342M 555.1M
Flexion Therapeutics FLXN:US $ 17.6M 5.6M
Halozyme Therapeutics HALO:US $ 97.24M 16.2M
IONIS PHARMACEUT IONS:US $ 130M 7.21M
Karyopharm Therapeutics KPTI:US $ 37.1M 15.64M
Ligand Pharmaceuticals LGND:US $ 53.39M 0.69M
MacroGenics MGNX:US 14M 16.74M
Neurocrine Biosciences NBIX:US $ 291.8M 6M
Pfizer PFE:US $ 14163M 2178M
Regeneron Pharmaceuticals REGN:US $ 2999.6M 1445.2M
Rigel Pharmaceuticals RIGL:US $ 21.39M 4.74M
Ultragenyx Pharmaceutical RARE:US $ 77.47M 6.37M
Veracyte VCYT:US $ 38.73M 1.09M